Status:
COMPLETED
Multi-modality MRI Study on Differences in Conversion of aMCI Patients With APOEε4 to AD
Lead Sponsor:
XuanwuH 2
Collaborating Sponsors:
Xuanwu Hospital, Beijing
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
Brief Summary
This study is to find out the imaging marker and the changing laws of the marker during the course of the disease. The final purpose is to provide scientific evidence for new prevention, diagnosis and...
Detailed Description
It is an urgent problem in the field of cognitive neuroscience to tell the conversion progression of amnestic mild cognitive impairment(aMCI) patients with Apolipoproteinε4(APOEε4) to Alzheimer's Dise...
Eligibility Criteria
Inclusion
- Complaint about memory loss and confirmed by an informant
- Cognitive impairment in single or multiple domains, adjusted for age and education
- Normal or near-normal performance on general cognitive function and no or minimum impairment of daily life activities
- A Clinical Dementia Rating (CDR) score is 0.5
- Failure to meet the criteria for dementia
- Carrying susceptible gene APOEε4
- Must be able to accept examination of MRI, sight and hearing allow to complete test
Exclusion
- Other diseases that cause cognitive impairment,such as thyroid disease,stroke and so on
- people who have severe visual and hearing impairment
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02225964
Start Date
January 1 2014
End Date
December 1 2018
Last Update
July 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurolgy,Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China, 100053